151 related articles for article (PubMed ID: 18813354)
41. Von Hippel-Lindau tumor suppressor protein and hypoxia-inducible factor in kidney cancer.
Maynard MA; Ohh M
Am J Nephrol; 2004; 24(1):1-13. PubMed ID: 14654728
[TBL] [Abstract][Full Text] [Related]
42. Von Hippel-Lindau disease.
Kaelin WG
Annu Rev Pathol; 2007; 2():145-73. PubMed ID: 18039096
[TBL] [Abstract][Full Text] [Related]
43. von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF.
Hoffman MA; Ohh M; Yang H; Klco JM; Ivan M; Kaelin WG
Hum Mol Genet; 2001 May; 10(10):1019-27. PubMed ID: 11331612
[TBL] [Abstract][Full Text] [Related]
44. Structural bioinformatics mutation analysis reveals genotype-phenotype correlations in von Hippel-Lindau disease and suggests molecular mechanisms of tumorigenesis.
Forman JR; Worth CL; Bickerton GR; Eisen TG; Blundell TL
Proteins; 2009 Oct; 77(1):84-96. PubMed ID: 19408298
[TBL] [Abstract][Full Text] [Related]
45. von Hippel Lindau tumor suppressor regulates hepatic glucose metabolism by controlling expression of glucose transporter 2 and glucose 6-phosphatase.
Park SK; Haase VH; Johnson RS
Int J Oncol; 2007 Feb; 30(2):341-8. PubMed ID: 17203215
[TBL] [Abstract][Full Text] [Related]
46. Characterization of a von Hippel Lindau pathway involved in extracellular matrix remodeling, cell invasion, and angiogenesis.
Kurban G; Hudon V; Duplan E; Ohh M; Pause A
Cancer Res; 2006 Feb; 66(3):1313-9. PubMed ID: 16452184
[TBL] [Abstract][Full Text] [Related]
47. Von Hippel-Lindau (VHL) disease: an update on the clinico-pathologic and genetic aspects.
Shehata BM; Stockwell CA; Castellano-Sanchez AA; Setzer S; Schmotzer CL; Robinson H
Adv Anat Pathol; 2008 May; 15(3):165-71. PubMed ID: 18434768
[TBL] [Abstract][Full Text] [Related]
48. Genetic study of a large Chinese kindred with von Hippel-Lindau disease.
Huang YR; Zhang J; Wang JD; Fan XD
Chin Med J (Engl); 2004 Apr; 117(4):552-7. PubMed ID: 15109448
[TBL] [Abstract][Full Text] [Related]
49. Expression of VHL and HIF-1α and Their Clinicopathologic Significance in Benign and Malignant Lesions of the Gallbladder.
Yang Z; Yang Z; Xiong L; Huang S; Liu J; Yang L; Miao X
Appl Immunohistochem Mol Morphol; 2011 Dec; 19(6):534-9. PubMed ID: 21415706
[TBL] [Abstract][Full Text] [Related]
50. Multiple neuroendocrine tumors of the pancreas in von Hippel-Lindau disease patients: histopathological and molecular genetic analysis.
Lubensky IA; Pack S; Ault D; Vortmeyer AO; Libutti SK; Choyke PL; Walther MM; Linehan WM; Zhuang Z
Am J Pathol; 1998 Jul; 153(1):223-31. PubMed ID: 9665483
[TBL] [Abstract][Full Text] [Related]
51. Von Hippel-Lindau syndrome: molecular mechanisms of the disease.
Calzada MJ
Clin Transl Oncol; 2010 Mar; 12(3):160-5. PubMed ID: 20231120
[TBL] [Abstract][Full Text] [Related]
52. Von Hippel-Lindau disease and endocrine tumour susceptibility.
Woodward ER; Maher ER
Endocr Relat Cancer; 2006 Jun; 13(2):415-25. PubMed ID: 16728571
[TBL] [Abstract][Full Text] [Related]
53. Allelic deletion and mutation of the von Hippel-Lindau (VHL) tumor suppressor gene in pancreatic microcystic adenomas.
Vortmeyer AO; Lubensky IA; Fogt F; Linehan WM; Khettry U; Zhuang Z
Am J Pathol; 1997 Oct; 151(4):951-6. PubMed ID: 9327728
[TBL] [Abstract][Full Text] [Related]
54. Parasympathetic paragangliomas are part of the Von Hippel-Lindau syndrome.
Gaal J; van Nederveen FH; Erlic Z; Korpershoek E; Oldenburg R; Boedeker CC; Kontny U; Neumann HP; Dinjens WN; de Krijger RR
J Clin Endocrinol Metab; 2009 Nov; 94(11):4367-71. PubMed ID: 19808854
[TBL] [Abstract][Full Text] [Related]
55. VHL and PTEN loss coordinate to promote mouse liver vascular lesions.
Chen S; Sanford CA; Sun J; Choi V; Van Dyke T; Samulski RJ; Rathmell WK
Angiogenesis; 2010 Mar; 13(1):59-69. PubMed ID: 20221685
[TBL] [Abstract][Full Text] [Related]
56. High frequency loss of heterozygosity in von Hippel-Lindau (VHL)-associated and sporadic pancreatic islet cell tumors: evidence for a stepwise mechanism for malignant conversion in VHL tumorigenesis.
Lott ST; Chandler DS; Curley SA; Foster CJ; El-Naggar A; Frazier M; Strong LC; Lovell M; Killary AM
Cancer Res; 2002 Apr; 62(7):1952-5. PubMed ID: 11929809
[TBL] [Abstract][Full Text] [Related]
57. Expression pattern of the von Hippel-Lindau protein in human tissues.
Los M; Jansen GH; Kaelin WG; Lips CJ; Blijham GH; Voest EE
Lab Invest; 1996 Aug; 75(2):231-8. PubMed ID: 8765323
[TBL] [Abstract][Full Text] [Related]
58. Hypoxia mediated expression of stem cell markers in VHL-associated hemangioblastomas.
Ponnaluri VK; Vavilala DT; Prakash S; Mukherji M
Biochem Biophys Res Commun; 2013 Aug; 438(1):71-7. PubMed ID: 23872148
[TBL] [Abstract][Full Text] [Related]
59. The expression of the von Hippel-Lindau gene product and its impact on invasiveness of human breast cancer cells.
Zia MK; Rmali KA; Watkins G; Mansel RE; Jiang WG
Int J Mol Med; 2007 Oct; 20(4):605-11. PubMed ID: 17786294
[TBL] [Abstract][Full Text] [Related]
60. Unilateral Papillary Cystadenoma of the Epididymis as a First Presentation of Von Hippel-Lindau Disease.
Miscia ME; Di Renzo D; Persico A; Tarallo L; Chiesa PL
Urology; 2018 Aug; 118():189-191. PubMed ID: 29729363
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
